Merck Submits European Marketing Authorization Application for Sapropterin as a Treatment for Hyperphenylalaninemia

Sapropterin has been granted Orphan Medicinal Product designation for the treatment of hyperphenylalaninemia

12-Nov-2007 - Merck KGaA announced that its division Merck Serono has submitted an application to the European Medicines Agency (EMEA) for the marketing authorization (MA) of sapropterin (INN: sapropterin dihydrochloride, formerly known as Phenoptin(TM)) as an oral treatment for significant ...

Betaseron approved in the U.S. for earliest stages of Multiple Sclerosis

25-Oct-2006 - Schering AG announced that the U.S. Food and Drug Administration (FDA) has expanded the indication of Betaseron (interferon beta-1b, brand name of Betaferon® in the U.S.) to include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. ...

Eisai Launches Antiasthmatic, Antitussive and Expectorant, ASTHPHYLLIN(R) S Tablets

24-Aug-2005 - Eisai Co., Ltd. announced that the Company launched ASTHPHYLLIN(R) S, a consumer health care medication to alleviate asthma, coughing and expectoration of sputum. ASTHPHYLLIN(R) S is an OTC (over-the-counter) version of ASTHPHYLLIN(R), an antiasthmatic drug for prescription use and has been ...

ALTANA: Top line results of first one-year COPD study with Daxas

05-Jul-2005 - Following the announcement of the termination of the Daxas® (roflumilast) collaboration with Pfizer, ALTANA disclosed the top line results of the first one-year COPD study of Daxas®. The phosphodiesterase4 (PDE4)-inhibitor Daxas® is an oral investigational, steroid free anti-inflammatory agent ...

ALTANA und Pfizer beenden Daxas-Kooperation

05-Jul-2005 - ALTANA und Pfizer haben vereinbart, die Daxas® (Roflumilast)-Kooperation zum 30. Juni 2005 zu beenden. Gemäß der Vereinbarung gibt Pfizer alle bezüglich Daxas® bestehenden Rechte an ALTANA zurück. ALTANA übernimmt die alleinige Verantwortung für die weitere Entwicklung von Daxas®, insbesondere ...

Assay from Bayer HealthCare determines hepatitis C viral load

FDA approval for HCV assay

07-Apr-2003 - Leverkusen - The Diagnostics Division of Bayer HealthCare in Tarrytown, N.Y., USA, has received approval from the American Food and Drug Administration (FDA) for a diagnostic test to determine the viral load in the blood of patients infected with hepatitis C. This is the only assay approved by ...

TOPIGEN Pharmaceuticals Inc. signs development and manufacturing agreement with The Dow Chemical Company

11-Mar-2003 - TOPIGEN Pharmaceuticals Inc. and The Dow Chemical Company recently signed a joint agreement for Dowpharma, Dow's pharmaceutical manufacturing services business unit, to supply select, proprietary oligonucleotides to TOPIGEN. TOPIGEN's pharmaceutical development program, based primarily on a ...

BP Leads Oil Industry with the Launch of Pioneering Sulphur-free Fuels

19-Feb-2002 - 18th February 2002 Edinburgh is the first city in the world to offer both Sulphur Free Unleaded and Sulphur Free Diesel, following another industry-leading cleaner fuels launch by BP. Sulphur Free Unleaded and Sulphur Free Diesel will be available at 18 BP service stations in the Edinburgh area ...

Aventis: New Drug Application for the Treatment of Viral Respiratory Infection (VRI, or the Common Cold)

Picovir™ (pleconaril) to be Reviewed by FDA Antiviral Drugs Advisory Committee on March 19, 2002

08-Feb-2002 - Aventis Pharmaceuticals Exton, PA, and Bridgewater, N.J., February 7, 2002 – ViroPharma Incorporated (Nasdaq: VPHM) and Aventis Pharmaceuticals, the U.S. pharmaceutical company of Aventis Pharma AG, today announced that the new drug application for Picovir™ (pleconaril), an investigational ...

BOEHRINGER INGELHEIM RECEIVES FIRST MARKETING AUTHORIZATION FOR SPIRIVA® (TIOTROPIUM)

18-Oct-2001 - Boehringer Ingelheim announced today that it has received an approval from the Medicinal Evaluation Board in Den Haag, Netherlands for its COPD drug Spiriva® (tiotropium). Spiriva’s approved indication is for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease - ...